Ropes & Gray advised Eli Lilly and Company (Lilly) in a strategic collaboration with Repertoire Immune Medicines, a biotechnology company that develops programmable T cell target immune medicines, to develop tolerizing therapies for multiple autoimmune diseases. The collaboration announced on January 29 aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression common in available therapies.
Under the agreement, Repertoire will receive an upfront payment of $85 million and up to an additional $1.84 billion for achieving certain development and commercial milestones and tiered royalties on net sales.
The Ropes & Gray team was led by life sciences licensing partner Abby Gregor and life sciences transactions partner Ray Grant.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.